[Expert recommendations on the use of teduglutide in pediatric patients with short bowel syndrome].

Autor:	Martínez MI; Hospital Universitario Fundación Favaloro, Buenos Aires, Argentina. E-mail: mimartin@ffavaloro.org., Balacco M; Hospital de Niños Santísima Trinidad, Córdoba, Argentina., Busoni V; Hospital Italiano de Buenos Aires, Argentina., Fernández A; Hospital Interzonal de Agudos Especializado en Pediatría (HIAEP) Sor María Ludovica, La Plata, Buenos Aires, Argentina., Rumbo C; Hospital Universitario Fundación Favaloro, Buenos Aires, Argentina.
Jazyk:	Spanish; Castilian
Zdroj:	Medicina [Medicina (B Aires)] 2023; Vol. 83 (1), pp. 114-121.
Abstrakt:	Short bowel syndrome is a low-incidence disorder among pediatric patients, but it is associated with high morbidity and mortality rates. Management of these patients by an interdisciplinary team of experts focused on intestinal rehabilitation improves short- and long-term outcomes. Available resources for treatment include teduglutide, a glucagon-like peptide type 2 (GLP-2) analog made by recombinant techniques. Considering the available evidence and the authors' experience, Delphi-based recommendations for the use of teduglutide are suggested for healthcare professionals who treat pediatric patients with short bowel syndrome, as well as for health authorities.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu